When is ASMB's latest earnings report released?
The most recent financial report for Assembly biosciences, inc. (ASMB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ASMB's short-term business performance and financial health. For the latest updates on ASMB's earnings releases, visit this page regularly.
How much debt does ASMB have?
As of the end of the reporting period, Assembly biosciences, inc. (ASMB) had total debt of 2.63M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ASMB have?
At the end of the period, Assembly biosciences, inc. (ASMB) held Total Cash and Cash Equivalents of 58.45M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ASMB go with three margins increasing?
In the latest report, Assembly biosciences, inc. (ASMB) achieved the “three margins increasing” benchmark, with a gross margin of 99.92%%, operating margin of 46.62%%, and net margin of 52.01%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ASMB's profit trajectory and future growth potential.
Is ASMB's EPS continuing to grow?
According to the past four quarterly reports, Assembly biosciences, inc. (ASMB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ASMB?
Assembly biosciences, inc. (ASMB)'s Free Cash Flow (FCF) for the period is 14.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 3,592.14% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ASMB?
The latest valuation data shows Assembly biosciences, inc. (ASMB) has a Price-To-Earnings (PE) ratio of -71.28 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
